Detalhe da pesquisa
1.
A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression.
Blood
; 143(16): 1599-1615, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394668
2.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med
; 387(24): 2232-2244, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507686
3.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661166
4.
Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial.
Br J Haematol
; 204(4): 1429-1438, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38348544
5.
Talquetamab in multiple myeloma.
Haematologica
; 109(3): 718-724, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855056
6.
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
Am J Hematol
; 98(1): 140-147, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567778
7.
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(27): 1823-1840, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492991
8.
Teclistamab, a B-cell maturation antigenâ×âCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Lancet
; 398(10301): 665-674, 2021 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388396
9.
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Biol Blood Marrow Transplant
; 26(4): 798-804, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31756536
10.
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.
Blood
; 131(7): 741-745, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29301755
11.
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 25(3): e89-e97, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408566
12.
Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(12): 2517-2521, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31445185
13.
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Blood
; 130(8): 974-981, 2017 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28637662
14.
Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation.
Biol Blood Marrow Transplant
; 24(5): 909-913, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29360515
15.
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
Biol Blood Marrow Transplant
; 24(3): 478-485, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079457
16.
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.
Biol Blood Marrow Transplant
; 24(3): 514-520, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196080
17.
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Cancer
; 124(22): 4342-4349, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30395359
18.
Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.
Blood
; 128(8): 1050-8, 2016 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27297790
19.
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Blood
; 127(13): 1656-65, 2016 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-26825712
20.
Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.
Biol Blood Marrow Transplant
; 23(6): 922-929, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28267593